Results of treatment with bedaquiline containing regimens of MDR/XDR tuberculosis patients including those with concurrent HIV infection (the experience of Leningrad Region)
https://doi.org/10.21292/2075-1230-2020-98-9-56-62
Abstract
The effectiveness of tuberculosis control is associated with efficacy of treatment of TB patients and above all patients with multiple and extensive drug resistance (MDR/XDR MTB). Patients with TB/HIV co-infection providethe significant impact on the situation.
The objective of the study is to assess outcomes of chemotherapy regimens containing bedaquiline in patients with MDR/XDR TB including those with concurrent HIV infection.
Subjects and methods. The efficacy and safety of the regimes containing bedaquiline were assessed in the intensive phase of chemotherapy in 80 patients with MDR/XDR TB: Group1 consisted of 46 patients with negative HIV status (ICD10 code A15-A19); Group 2 – 34 HIV positive patients at the advanced stage with manifestations of a mycobacterial infection (ICD10 code B20.0).
Results. Treatment outcomes in the groups were as follows: the effective treatment was statistically significantly more frequent in Group 1 versus Group 2 (80.4 and 52.9%, respectively, p = 0.0088). Treatment failure was registered in 3 patients from each group; treatment defaults were statistically significantly more frequent in Group 2 compared to Group 1: in 8/34 versus 2/46 (p = 0.011). 3 patients were transferred out in both Group 1 and Group 2 (3/46 and 3/34, p = 0.69). During treatment, only 1 patient from Group 2 developed an adverse event, most likely associated with the in-take of bedaquiline, a heart rhythm disorder (ventricular arrhythmia) and prolongation of QTcF > 450 ms.
About the Authors
T. I. Danilova
Leningrad Regional TB Dispensary, Slantsy
Russian Federation
Russian Federation
Candidate of Medical Sciences, Deputy Chief Physician for Medical Activities,
5, Nogina St., St. Petersburg, 192029
Yu. V. Korneev
Leningrad Regional TB Dispensary, Slantsy
Russian Federation
Russian Federation
Head Physician, Chief TB Expert of Leningrad Region,
5, Nogina St., St. Petersburg, 192029
D. A. Kudlay
Immunology Research Institute by the Federal Medical Biological Agency;
I. M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Leading Researcher of Laboratory of Personalized Medicine and Molecular Immunology no. 71, 24, Kashirskoye Highway, Moscow, 115478;
Doctor of Medical Sciences, Professor of Pharmacology Department of Pharmaceutical Science Institute, 8, Bd. 2, Trubetskaya St., Moscow, 119991
N. Yu. Nikolenko
Moscow Scientific Practical Center of Tuberculosis Control
Russian Federation
Russian Federation
Researcher,
10, Stromynka St., Moscow, 107014
References
1. Balasanyants G.S. Experience of using bedaquiline in the multimodality therapy of tuberculosis patients with concurrent HIV infection. Tuberculosis and Lung Diseases, 2017, no. 9, pp. 49-54. (In Russ.)
2. Borisov S.E., Filippov А.V., Ivanova D.А., Ivanushkina T.N., Litvinova N.V., Garmash Yu.Yu. Efficacy and safety of chemotherapy regimens containing bedaquiline in respiratory tuberculosis patients: immediate and final results. Tuberculosis and Lung Diseases, 2019, vol. 97, no. 5, pp. 28-40. (In Russ.) http://doi.org/10.21292/2075-1230-2019-97-5-28-40.
3. Golubchikov P.N., Kruk E.А., Mishustin S.P., Petrenko T.I., Kudlay D.А. Experience of treating extensive drug resistant tuberculosis patients including continuous use of bedaquiline, in Tomsk Region: immediate and postponed results. Tuberculosis and Lung Diseases, 2019, vol. 97, no. 8, pp. 38-45. (In Russ.)
4. Use guidelines for Sirturo®. LP-002281, 17.07.2015. (In Russ.)
5. Morozova T.I., Otpuschennikova O.N., Doktorova N.P., Danilov А.N. Experience of using bedaquiline in the treatment of pulmonary tuberculosis patients with multiple drug resistance. Tuberculosis and Lung Diseases, 2016, no. 2, pp. 29-35. (In Russ.)
6. On Approval of Clinical Guidelines on Improvement of Diagnostics and Treatment of Respiratory Tuberculosis. Approved by Edict no. 951 by the Russian Ministry of Health as of 29.12.2014. (In Russ.)
7. Stavitskaya N.V., Felker I.G., Zhukova E.M., Tlif А.I., Doktorova N.P., Kudlay D.А.The multivariate analysis of the results of bedaquiline use in the therapy of MDR/XDR pulmonary tuberculosis Tuberculosis and Lung Diseases, 2020, vol. 98, no. 7, pp. 56-62. (In Russ>) http://doi.org/10.21292/2075-1230-2020-98-7-56-62.
8. Tikhonova L.Yu., Sokolova V.V., Tarasyuk I.А., Ekimenko А.M., Cherenkova M.А., Kudlay D.А. Experience of treatment of multiple drug resistant tuberculosis patients with bedaquiline in Amur Region. Tuberculosis and Lung Diseases, 2018, vol. 96, no. 6, pp. 45-50. (In Russ.)
9. Federalnye klinicheskiye rekomendatsii po diagnostike i lecheniyu tuberkuleza organov dykhaniya s mnozhestvennoy i shirokoy lekarstennoy ustoichivostyu vozbuditelya. [Federal clinical recommendations for diagnosis and treatment of respiratory tuberculosis with multiple and extensive drug resistance]. Moscow, 3r Ed., ROF Publ., pp.17, 33.
10. Dheda K., Shean K., Zumla A. et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet, 2010, vol. 375, pp. 1798-1807.
11. Gopalan N., Chandrasekaran P., Swaminathan S., Tripathy S. Current trends and intricacies in the management of HIV-associated pulmonary tuberculosis. AIDS Res.Therap., 2016, vol. 13, pp. 34.
12. Ndjeka N., Conradie F., Schnippel K. et al. Treatment of drugresistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis. Int.J.Tuberc.Lung Dis., 2015, vol. 19, pp. 979-985.
13. WHO consolidated guidelines on drug-resistant tuberculosis treatment. WHO, 2019.
Review
For citations:
Danilova T.I., Korneev Yu.V., Kudlay D.A., Nikolenko N.Yu. Results of treatment with bedaquiline containing regimens of MDR/XDR tuberculosis patients including those with concurrent HIV infection (the experience of Leningrad Region). Tuberculosis and Lung Diseases. 2020;98(9):56-62. (In Russ.) https://doi.org/10.21292/2075-1230-2020-98-9-56-62
Views:
769
Email this article 